Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.

doi:10.1093/neuonc/noaf133

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.

Neuro-oncology - 14 Oct 2025

Lasica Aleksandra B, Lan Zhou, Miller Julie J, Jiao Albert, Pan Ian, Aker Loai, Prabhakar Prem, Japo Julia, Russ Alyssa, Westergaard Catharina, Aquilanti Elisa, Chukwueke Ugonma, Gonzalez Castro L Nicolas, McFaline Figueroa J Ricardo, Lee Eudocia Quant, Nayak Lakshmi, Beroukhim Rameen, Batchelor Tracy T, Cahill Daniel P, Nakhate Vihang, Lanman Tyler, Pablo Ospina Juan, Stec Natalie, Patel Ruchit V, Meredith David M, Bi Wenya Linda, Reardon David A, Ligon Keith L, Huang Raymond Y, Wen Patrick Y, Youssef Gilbert

Abstract excerpt

BACKGROUND: Astrocytoma, isocitrate dehydrogenase-mutant, WHO grade 4 (Astro4), is a new tumor type in the 2021 WHO classification of central nervous system tumors that has been poorly characterized in the literature. This study evaluates predictors of prognosis in a large cohort of newly diagnosed Astro4. METHODS: We retrospectively identified 128 consecutive adult patients who presented with an initial...

Topics

Humans
Male
Female
Astrocytoma
Isocitrate Dehydrogenase
Adult
Prognosis
Middle Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Retrospective Studies

Mutation

Brain Neoplasms

Survival Rate

Follow-Up Studies

Young Adult

Aged

Biomarkers, Tumor

Neoplasm Grading

Adolescent

Source

Open in PubMed Open full text

Identifiers

PMID: 40440464
DOI: 10.1093/neuonc/noaf133
PMCID: PMC12526062

Genes

CDKN2A
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.PMID 40440464Read ↗

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.Semantic proximity Read ↗

Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.Semantic proximity Read ↗

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Semantic proximity Read ↗

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Semantic proximity Read ↗

Expanding the molecular grading criteria in IDH-mutant astrocytoma.Semantic proximity Read ↗

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.Semantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.Semantic proximity Read ↗

Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.Semantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.